

Resource Summary Report

Generated by [RRID](#) on Sep 11, 2026

PI3 Kinase p110alpha (C73F8) Rabbit mAb

RRID:AB_2165248

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 4249, RRID:AB_2165248)

Antibody Information

URL: http://antibodyregistry.org/AB_2165248

Proper Citation: (Cell Signaling Technology Cat# 4249, RRID:AB_2165248)

Target Antigen: PI3 Kinase p110alpha

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IP

Consolidation on 10/2018: AB_10288241, AB_10828217, AB_2165248.

Antibody Name: PI3 Kinase p110alpha (C73F8) Rabbit mAb

Description: This recombinant monoclonal targets PI3 Kinase p110alpha

Target Organism: rat, mouse, bovine, human

Clone ID: C73F8

Antibody ID: AB_2165248

Vendor: Cell Signaling Technology

Catalog Number: 4249

Record Creation Time: 20260408T215516+0000

Record Last Update: 20260828T175955+0000

Ratings and Alerts

No rating or validation information has been found for PI3 Kinase p110alpha (C73F8) Rabbit mAb.

No alerts have been found for PI3 Kinase p110alpha (C73F8) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 55 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tang S, et al. (2026) PTEN Loss Promotes PI3K γ Phosphorylation and EPHA2/SRC/p-PI3K γ Y962 Complex Assembly to Drive Tumorigenesis. *Cancer discovery*, 16(3), 521.

Long F, et al. (2026) MEDAG functions as an A-kinase-anchoring protein in adipocytes. *Molecular cell*, 86(5), 937.

Meitei HT, et al. (2026) CCL20-CCR6 signaling alters the metabolic reprogramming to promote the pathogenic Th17 cell differentiation. *iScience*, 29(1), 114385.

Juric D, et al. (2026) PI3K γ Inhibitor and Degradar Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(1), 56.

Ye Q, et al. (2026) Akt2 regulates autophagy and osteogenesis in diabetic osteoporosis via PI3K/AKT/mTOR signaling axis. *Bone*, 204, 117770.

Ding J, et al. (2026) CDC20 promotes prostate cancer progression via modulating c-MYC and PI3K-AKT signaling. *iScience*, 29(7), 116409.

Yu L, et al. (2026) Activin A enhances neurofunctional recovery following traumatic spinal cord injury by inhibiting autophagy. *Neural regeneration research*, 21(6), 2485.

Li H, et al. (2025) Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. *Cell reports. Medicine*, 6(2), 101927.

Su X, et al. (2025) Mesothelin as a biomarker and potential therapeutic target in rheumatoid arthritis bone destruction. *Cell reports. Medicine*, 6(11), 102430.

Lee Q, et al. (2025) Deficiency in N-cadherin-Akt3 signaling impairs the blood-brain barrier. *Cell reports*, 44(6), 115831.

Tomlinson PR, et al. (2025) Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant. *eLife*, 13.

Zhang Y, et al. (2025) TREM2 activation reduces white matter injury via PI3K/Akt/GSK-3 β signalling after intracerebral haemorrhage. *British journal of pharmacology*, 182(11), 2542.

Dennaoui R, et al. (2025) STAT-independent functions of Janus kinases 1 and 2 are obligatory for the postnatal development of mammary epithelial ducts. *Cell reports*, 45(1), 116703.

Song L, et al. (2025) Penfluridol targets septin7 to suppress endometrial cancer by septin7-Orai/IP3R-Ca²⁺-PIK3CA pathway. *iScience*, 28(1), 111640.

Jiang Y, et al. (2025) USP8 deubiquitylation-boosted NSUN4 potentiates lung squamous cell carcinoma progression by m5C methylation of DHCR24. *Cell reports*, 44(8), 116158.

Lei J, et al. (2025) Neuroprotective effects of Yangming-Kaixin-Yizhi formula in Alzheimer's disease: dual regulation of PI3K/Akt and p38 MAPK signaling via network pharmacology and experimental approaches. *Metabolic brain disease*, 40(7), 254.

Bagchi A, et al. (2025) PDE4 inhibitor rolipram represses hedgehog signaling via ubiquitin-mediated proteolysis of GLI transcription factors to regress breast cancer. *The Journal of biological chemistry*, 301(3), 108239.

Burge RA, et al. (2025) PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. *Cancer research*, OF1.

Zhou Y, et al. (2025) Soluble CSF1R alleviates microgliopathy in a CSF1R-related leukoencephalopathy (CRL) mouse model. *Journal of neuroinflammation*, 23(1), 12.

Chen H, et al. (2024) PIK3CA mutations enhance the adipogenesis of ADSCs in facial infiltrating lipomatosis through TRPV1. *iScience*, 27(8), 110467.